A neuroblastoma-selective suicide gene therapy approach using the tyrosine hydroxylase promoter

Pediatric Research

Volumn 56, Issue 2, 2004, Pages 268-277

  Steffens, Sabine ^a   Sandquist, Anke ^a   Frank, Susanne ^a   Fischer, Ute ^a   Lex, Christiane ^a   Rainov, Nikolai G ^b   Kramm, Christof M ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE BETA MONOOXYGENASE; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; NEURON SPECIFIC ENOLASE; RETROVIRUS VECTOR; THYMIDINE KINASE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DBHP GENE; EGFP GENE; EVALUATION; FLUORESCENCE ACTIVATED CELL SORTING; FUSION GENE; GENE; GENE CASSETTE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; NSEP GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FOLDING; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SUICIDE GENE; THP GENE; TUMOR CELL CULTURE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CHILD; GANCICLOVIR; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, REPORTER; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; IMMUNOMAGNETIC SEPARATION; MICE; NEUROBLASTOMA; PROMOTER REGIONS (GENETICS); TRANSDUCTION, GENETIC; TYROSINE 3-MONOOXYGENASE;

EID: 3242781845     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000132666.23103.EF     Document Type: Article

References (38)

1. Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan PA, Paulus W, Chiocca EA, Breakefield XO 1995 Gene therapy for brain tumors. Brain Pathol 5:345-381
2. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH 1997 Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354-1361
3. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM 1992 In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-1552
4. Brand K, Loser P, Arnold W, Bartels T, Strauss M 1998 Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Ther 5:1363-1371
5. Forss-Petter S, Danielson PE, Catsicas S, Battenberg E, Price J, Nerenberg M, Sutcliffe JG 1990 Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron 5:187-197
6. Twyman RM, Jones EA 1997 Sequences in the proximal 5′ flanking region of the rat neuron-specific enolase (NSE) gene are sufficient for cell type-specific reporter gene expression. J Mol Neurosci 8:63-73
7. Coker GT, Vinnedge L, O'Malley KL 1988 Characterization of rat and human tyrosine hydroxylase genes: functional expression of both promoters in neuronal and non-neuronal cell types. Biochem Biophys Res Commun 157:1341-1347
8. Kobayashi K, Kurosawa Y, Fujita K, Nagatsu T 1989 Human dopamine beta-hydroxylase gene: two mRNA types having different 3′-terminal regions are produced through alternative polyadenylation. Nucleic Acids Res 17:1089-1102
9. Shaskus J, Greco D, Asnani LP, Lewis EJ 1992 A bifunctional genetic regulatory element of the rat dopamine beta-hydroxylase gene influences cell type specificity and second messenger-mediated transcription. J Biol Chem 267:18821-18830
10. Andersen JK, Garber DA, Meaney CA, Breakefield XO 1992 Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum Gene Ther 3:487-499
11. Morgenstern JP, Land H 1990 Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18:3587-3696
12. Steffens S, Frank S, Fischer U, Heuser C, Meyer KL, Dobberstein KU, Rainov NG, Kramm CM 2000 Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy. Cancer Gene Ther 7:806-812
13. Gardaneh M, Gilbert J, Haber M, Norris MD, Cohn SL, Schmidt ML, Marshall GM 2000 Synergy between 5′ and 3′ flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells. Neurosci Lett 292:147-150
14. Tanaka M, Inase N, Miyake S, Yoshizawa Y 2001 Neuron specific enolase promotor for suicide gene therapy in small cell lung carcinoma. Anticancer Res 21:291-294
15. LaBrosse EH, Comoy E, Bohuon C, Zucker JM, Schweisguth O 1976 Catecholamine metabolism in neuroblastoma. J Natl Cancer Inst 57:633-638
16. Chamberlain J 1994 Screening for neuroblastoma: a review of the evidence. J Med Screen 1:169-175
17. Elion GB 1983 The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 12(suppl B):9-17
18. Rainov NG 2000 A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401
19. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL 2000 Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7:867-87420.
20. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, Grossman RG 2000 Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1:195-203
21. Miltenyi S, Muller W, Weichel W, Radbruch A 1990 High gradient magnetic cell separation with MACS. Cytometry 11:231-238
22. Apperley JF, Luskey BD, Williams DA 1991 Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long-term expression. Blood 78:310-317
23. Bowtell DD, Cory S, Johnson GR, Gonda TJ 1988 Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. J Virol 62:2464-2473
24. Correll PH, Colilla S, Karlsson S 1994 Retroviral vector design for long-term expression in murine hematopoietic cells in vivo. Blood 84:1812-1822
25. Emerman M, Temin HM 1984 Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39:449-467
26. Vile R, Miller N, Chernajovsky Y, Hart I 1994 A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther 1:307-316
27. Yee JK, Moores JC, Jolly DJ, Wolff JA, Respess JG, Friedmann T 1987 Gene expression from transcriptionally disabled retroviral vectors. Proc Natl Acad Sci USA 84:5197-5201
28. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF, Gilboa E 1986 Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 83:3194-3198
29. Gilboa E, Eglitis MA, Kantoff PW, Anderson WF 1986 Transfer and expression of cloned genes using retroviral vectors. Biotechnology 4:504-512
30. Diaz RM, Eisen T, Hart IR, Vile RG 1998 Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol 72:789-795
31. Mavria G, Jager U, Porter CD 2000 Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther 7:368-376
32. Belmont JW, MacGregor GR, Wager-Smith K, Fletcher FA, Moore KA, Hawkins D, Villalon D, Chang SM, Caskey CT 1988 Expression of human adenosine deaminase in murine hematopoietic cells. Mol Cell Biol 8:5116-5125
33. Chang BD, Roninson IB 1996 Inducible retroviral vectors regulated by lac repressor in mammalian cells. Gene 183:137-142
34. Ragheb JA, Couture L, Mullen C, Ridgway A, Morgan RA 1999 Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev. Hum Gene Ther 10:103-112
35. Moolten FL, Wells JM 1990 Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82:297-300
36. Aghi M, Hochberg F, Breakefield XO 2000 Prodrug activation enzymes in cancer gene therapy. J Gene Med 2:148-164
37. Frank S, Steffens S, Fischer U, Tlolko A, Rainov NG, Kramm CM 2002 Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy. Cancer Gene Ther 9:178-188
38. Aghi M, Kramm CM, Breakefield XO 1999 Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 91:1233-1241